JSPR Stock Analysis: Buy, Sell, or Hold?
JSPR - Jasper Therapeutics, Inc. Common Stock
$0.80
-0.08 (-8.70%)
▼
5d:
-26.61%
30d:
-39.85%
90d:
-55.31%
WAIT
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 02, 2026
0d
Get Alerted When JSPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: JSPR is down 26.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: JSPR is down 26.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: JSPR is currently trading at $0.80, which is considered oversold relative to its 30-day fair value range of $1.07 to $1.40.
Technical Outlook: Technically, JSPR is in a strong downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.70 (+987.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JSPR is in a strong downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.70 (+987.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.07 -
$1.40
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.7%)
- BULLISH: Trading 987.5% below Wall St target ($8.70)
- WARNING: Recommendation downgraded due to -26.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.07 -
$1.40
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.27
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.50
Wall Street Target
$8.70
(+987.5%)
Share & Embed Analysis
Last updated: April 02, 2026 3:57 AM ET
Data refreshes hourly during market hours. Next update: 4:57 AM
Data refreshes hourly during market hours. Next update: 4:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JSPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
